Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Von-Hippel Lindau (VHL) gene inactivation is common in clear cell renal cell carcinoma (ccRCC), leading to stable expression of hypoxia-inducible factors (HIFs).
• While HIF1α (hypoxia-inducible factor 1 alpha) acts as a tumor suppressor in ccRCC, HIF2α (hypoxia-inducible factor 2 alpha) promotes tumor growth, creating a counterintuitive scenario in VHL-deficient tumors expressing both.
• Understanding the regulatory mechanisms governing HIF1α and HIF2α expression is crucial for ccRCC treatment strategies.

Purpose of the Study:

• To investigate the role of specific microRNAs (miRNAs) in regulating HIF2α expression in VHL-deficient ccRCC.
• To elucidate the mechanism by which miR-30c-2-3p and miR-30a-3p influence ccRCC tumor growth.
• To explore the interplay between HIF1α, HIF2α, and miRNAs in the context of VHL deficiency.

Main Methods:

• Utilized bioinformatics analysis to identify potential miRNA targets.
• Performed molecular biology techniques including gene expression analysis and miRNA profiling.
• Conducted cell culture experiments with ccRCC cell lines and in vivo xenograft studies in mice.

Main Results:

• Demonstrated that miR-30c-2-3p and miR-30a-3p directly target and inhibit HIF2A transcripts.
• Showed selective repression of the miR-30c-2-3p/miR-30a-3p locus in VHL-deficient ccRCC tumors expressing both HIF1α and HIF2α (H1H2 tumors).
• Found that inhibiting miR-30a-3p in H1H2 ccRCC cells increased HIF2α levels, promoting cellular proliferation, angiogenesis, and tumor growth in xenografts.

Conclusions:

• Repression of miR-30c-2-3p and miR-30a-3p is a key mechanism enhancing HIF2α expression in VHL-deficient H1H2 ccRCC.
• This miRNA repression attenuates the tumor-suppressive effects of constitutive HIF1α expression, thereby promoting ccRCC progression.
• Targeting these miRNAs could represent a novel therapeutic strategy for VHL-deficient ccRCC.